Historique
Article de Périodique
Buprenorphine implants for treatment of opioid dependence: randomized comparison to placebo and sublingual buprenorphine/naloxone (2013)
Auteur(s) :
ROSENTHAL, R. N. ;
LING, W. ;
CASADONTE, P. ;
VOCCI, F. ;
BAILEY, G. L. ;
KAMPMAN, K. ;
PATKAR, A. A. ;
CHAVOUSTIE, S. ;
BLASEY, C. ;
SIGMON, S. C. ;
BEEBE, K. L.
Année :
2013
Page(s) :
2141-2149
Langue(s) :
Anglais
Refs biblio. :
21
Domaine :
Drogues illicites / Illicit drugs
Thésaurus géographique
ETATS-UNIS
Thésaurus mots-clés
ETUDE RANDOMISEE
;
BUPRENORPHINE
;
COMPARAISON
;
VOIE D'ADMINISTRATION
;
TRAITEMENT DE MAINTENANCE
;
OPIOIDES
;
EFFICACITE
;
PRODUIT DE SUBSTITUTION
Note générale :
Commentary: Buprenorphine implant - new hopes, old questions. Basu D., p. 2150-2151.
Résumé :
Aims: To evaluate the safety and efficacy of buprenorphine implants (BI) versus placebo implants (PI) for the treatment of opioid dependence. A secondary aim compared BI to open-label sublingual buprenorphine/naloxone tablets (BNX).
Design: Randomized, double-blind, placebo-controlled trial. Subjects received either four buprenorphine implants (80 mg/implant) (n = 114), four placebo implants (n = 54) or open-label BNX (12-16 mg/day) (n = 119).
Setting: Twenty addiction treatment centers.
Participants: Adult out-patients (ages 18-65) with DSM-IV-TR opioid dependence.
Measurements: The primary efficacy end-point was the percentage of urine samples negative for opioids collected from weeks 1 to 24, examined as a cumulative distribution function (CDF).
Findings: The BI CDF was significantly different from placebo (P Conclusions: Compared with placebo, buprenorphine implants result in significantly less frequent opioid use and are non-inferior to sublingual buprenorphine/naloxone tablets.
Design: Randomized, double-blind, placebo-controlled trial. Subjects received either four buprenorphine implants (80 mg/implant) (n = 114), four placebo implants (n = 54) or open-label BNX (12-16 mg/day) (n = 119).
Setting: Twenty addiction treatment centers.
Participants: Adult out-patients (ages 18-65) with DSM-IV-TR opioid dependence.
Measurements: The primary efficacy end-point was the percentage of urine samples negative for opioids collected from weeks 1 to 24, examined as a cumulative distribution function (CDF).
Findings: The BI CDF was significantly different from placebo (P Conclusions: Compared with placebo, buprenorphine implants result in significantly less frequent opioid use and are non-inferior to sublingual buprenorphine/naloxone tablets.
Affiliation :
Department of Psychiatry, St. Luke's-Roosevelt Hospital Center, Columbia University College of Physicians and Surgeons, New York, NY, USA
Cote :
Abonnement